Lineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Lineage Cell Therapeutics is expected to report its Q2 2025 earnings on August 12, with analysts anticipating a loss of ($0.02) per share and revenue of $1.47 million.
• The company's stock price recently increased to $0.99, with a market capitalization of $226.05 million and institutional investors owning approximately 62.47% of its shares.
• Analysts maintain a positive outlook with a consensus target price of $4.20, and several reports rate the stock as a "buy."

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.02) per share and revenue of $1.47 million for the quarter.

Lineage Cell Therapeutics Stock Up 3.5%

NYSEAMERICAN:LCTX traded up $0.03 during midday trading on Friday, reaching $0.98. The stock had a trading volume of 657,585 shares, compared to its average volume of 1,539,222. The firm has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $0.67. Lineage Cell Therapeutics has a 12-month low of $0.37 and a 12-month high of $1.21. The stock has a market cap of $224.80 million, a P/E ratio of -12.31 and a beta of 1.66.

Institutional Trading of Lineage Cell Therapeutics

A hedge fund recently raised its stake in Lineage Cell Therapeutics stock. Royal Bank of Canada boosted its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 1,578.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 528,656 shares of the company's stock after buying an additional 497,168 shares during the period. Royal Bank of Canada owned 0.24% of Lineage Cell Therapeutics worth $237,000 as of its most recent SEC filing. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LCTX has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. D. Boral Capital restated a "buy" rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday, August 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Lineage Cell Therapeutics presently has a consensus rating of "Buy" and an average target price of $4.20.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.